Liver-Specific Ionizable Lipid Nanoparticles Mediated Efficient RNA Interference to Clear "Bad Cholesterol"

Area of Science:

• Biotechnology
• Cardiovascular Research
• Gene Therapy

Background:

• High LDL-C is a key factor in atherosclerotic cardiovascular disease.
• PCSK9 protein regulates LDL receptors (LDLRs) and plasma LDL-C levels.
• Reducing PCSK9 expression up-regulates liver LDLRs and lowers LDL-C.

Purpose of the Study:

• To develop liver-specific nanoparticles for efficient siRNA delivery.
• To target hepatocytes for gene silencing of Pcsk9.
• To evaluate the therapeutic potential for lowering LDL-C.

Main Methods:

• Development of liver-specific ionizable lipid nanoparticles (GLP) for siRNA delivery.
• Nanoparticles feature high stability and a membrane-active polymer for targeted release.
• In vitro and in vivo studies to assess gene silencing and LDL-C reduction.

Main Results:

• GLP nanoparticles achieved 90% Pcsk9 mRNA silencing in vitro.
• In vivo studies showed a 3.35-fold increase in liver LDLR levels.
• Plasma LDL-C was reduced by 35% in vivo.

Conclusions:

• GLP nanoparticles demonstrate potent LDL-C lowering effects.
• This technology offers a potential therapeutic strategy for atherosclerotic cardiovascular disease.
• Targeted siRNA delivery to hepatocytes is effective for managing hypercholesterolemia.